Corrigendum to ‘Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer’ [European Journal of Cancer 76 (2017) 36–44]
Titel:
Corrigendum to ‘Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer’ [European Journal of Cancer 76 (2017) 36–44]
Auteur:
Massard, Christophe Chi, Kim Nguyen Castellano, Daniel de Bono, Johann Gravis, Gwenaelle Dirix, Luc Machiels, Jean-Pascal Mita, Alain Mellado, Begoña Turri, Sabine Maier, Joan Csonka, Denes Chakravartty, Arunava Fizazi, Karim